CTX-112 is under clinical development by CRISPR Therapeutics and currently in Phase II for Follicular Lymphoma. According to GlobalData, Phase II drugs for Follicular Lymphoma have a 43% phase ...
"These people smugglers are once again dicing with death But the ones taking the risks are the migrants not the smugglers.“ A Home Office spokesperson said: “We all want to end dangerous small boat ...
CTX-320 is under clinical development by CRISPR Therapeutics and currently in Phase I for Atherosclerosis. According to GlobalData, Phase I drugs for Atherosclerosis have a 64% phase transition ...
Makoto Uchida, Director, Representative Executive Officer, President and CEO of Nissan Motor Corporation and Toshihiro Mibe, Director, President and Representative Executive Officer of Honda.
Honda Motor Co. sketched plans for a drawn-out deal that amounts to an acquisition of Nissan Motor Co., as Japan’s automakers struggle to keep up in an increasingly competitive global car industry.
Honda appears to be the dominant partner in that it will nominate a majority of both the internal and external directors for the joint holding company. Merger talks accelerated from a March ...
Japanese rivals Honda Motor Co. and Nissan Motor Corp. confirmed Monday they are moving forward with merger talks to forge the world's third-largest car company by sales, aiming to find ...
Nissan and Honda have announced plans to merge by 2026 in a seismic shift for the Japanese auto industry. The two carmakers signed a memorandum of understanding that allows them to continue ...
Copyright 2025 The Associated Press. All Rights Reserved. Nissan Chief Executive Makoto Uchida, left, and Honda Chief Executive Toshihiro Mibe, center, and Takao Kato ...
The surging popularity of electric and hybrid vehicles made by BYD and others has erased the leading position that Japan’s automakers once enjoyed as providers of high-quality cars with cache.